David Young - 24 Jul 2025 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Pres. Research & Development, Director
Signature: /s/ David Young by John J. Wolfel, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 24 Jul 2025
Transactions value $: $0
Form type: 4/A - Amendment
Filing time: 18 Sep 2025, 16:24:44 UTC
Date Of Original Report: 28 Jul 2025
Previous filing: 11 Apr 2025
Next filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Young David	Pres. Research & Development, Director	C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	18 Sep 2025	0001378166

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PCSA	Common Stock						217K	24 Jul 2025	Direct
holding	PCSA	Common Stock						31K	24 Jul 2025	By Young-Plaisance Revocable Trust
holding	PCSA	Common Stock						10.8K	24 Jul 2025	By Family Entities
holding	PCSA	Common Stock						18.5K	24 Jul 2025	By CorLyst, LLC

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.